131 related articles for article (PubMed ID: 37264610)
1. Tau in dementia with Lewy bodies.
Chin KS; Churilov L; Doré V; Villemagne VL; Rowe CC; Yassi N; Watson R
Aust N Z J Psychiatry; 2024 Feb; 58(2):175-182. PubMed ID: 37264610
[TBL] [Abstract][Full Text] [Related]
2. Plasma Phospho-Tau Identifies Alzheimer's Co-Pathology in Patients with Lewy Body Disease.
Hall S; Janelidze S; Londos E; Leuzy A; Stomrud E; Dage JL; Hansson O
Mov Disord; 2021 Mar; 36(3):767-771. PubMed ID: 33285015
[TBL] [Abstract][Full Text] [Related]
3. Distinct patterns of amyloid-dependent tau accumulation in Lewy body diseases.
Lee SH; Cho H; Choi JY; Lee JH; Ryu YH; Lee MS; Lyoo CH
Mov Disord; 2018 Feb; 33(2):262-272. PubMed ID: 29168583
[TBL] [Abstract][Full Text] [Related]
4. Amyloid-β deposition and regional grey matter atrophy rates in dementia with Lewy bodies.
Sarro L; Senjem ML; Lundt ES; Przybelski SA; Lesnick TG; Graff-Radford J; Boeve BF; Lowe VJ; Ferman TJ; Knopman DS; Comi G; Filippi M; Petersen RC; Jack CR; Kantarci K
Brain; 2016 Oct; 139(Pt 10):2740-2750. PubMed ID: 27452602
[TBL] [Abstract][Full Text] [Related]
5. Association between amyloid-beta deposition and cortical thickness in dementia with Lewy bodies.
Chin KS; Gajamange S; Desmond PM; Villemagne VL; Rowe CC; Churilov L; Yassi N; Watson R
Aust N Z J Psychiatry; 2023 Apr; 57(4):594-602. PubMed ID: 35196886
[TBL] [Abstract][Full Text] [Related]
6. The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging.
Gordon BA; Friedrichsen K; Brier M; Blazey T; Su Y; Christensen J; Aldea P; McConathy J; Holtzman DM; Cairns NJ; Morris JC; Fagan AM; Ances BM; Benzinger TL
Brain; 2016 Aug; 139(Pt 8):2249-60. PubMed ID: 27286736
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes.
Mielke MM; Frank RD; Dage JL; Jeromin A; Ashton NJ; Blennow K; Karikari TK; Vanmechelen E; Zetterberg H; Algeciras-Schimnich A; Knopman DS; Lowe V; Bu G; Vemuri P; Graff-Radford J; Jack CR; Petersen RC
JAMA Neurol; 2021 Sep; 78(9):1108-1117. PubMed ID: 34309632
[TBL] [Abstract][Full Text] [Related]
8. Plasma Core Alzheimer's Disease Biomarkers Predict Amyloid Deposition Burden by Positron Emission Tomography in Chinese Individuals with Cognitive Decline.
Ni M; Zhu ZH; Gao F; Dai LB; Lv XY; Wang Q; Zhu XX; Xie JK; Shen Y; Wang SC; Xie Q;
ACS Chem Neurosci; 2023 Jan; 14(1):170-179. PubMed ID: 36547971
[TBL] [Abstract][Full Text] [Related]
9. Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography.
Therriault J; Vermeiren M; Servaes S; Tissot C; Ashton NJ; Benedet AL; Karikari TK; Lantero-Rodriguez J; Brum WS; Lussier FZ; Bezgin G; Stevenson J; Rahmouni N; Kunach P; Wang YT; Fernandez-Arias J; Socualaya KQ; Macedo AC; Ferrari-Souza JP; Ferreira PCL; Bellaver B; Leffa DT; Zimmer ER; Vitali P; Soucy JP; Triana-Baltzer G; Kolb HC; Pascoal TA; Saha-Chaudhuri P; Gauthier S; Zetterberg H; Blennow K; Rosa-Neto P
JAMA Neurol; 2023 Feb; 80(2):188-199. PubMed ID: 36508198
[TBL] [Abstract][Full Text] [Related]
10. AV-1451 tau and β-amyloid positron emission tomography imaging in dementia with Lewy bodies.
Kantarci K; Lowe VJ; Boeve BF; Senjem ML; Tosakulwong N; Lesnick TG; Spychalla AJ; Gunter JL; Fields JA; Graff-Radford J; Ferman TJ; Jones DT; Murray ME; Knopman DS; Jack CR; Petersen RC
Ann Neurol; 2017 Jan; 81(1):58-67. PubMed ID: 27863444
[TBL] [Abstract][Full Text] [Related]
11. Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum.
Moscoso A; Grothe MJ; Ashton NJ; Karikari TK; Rodriguez JL; Snellman A; Suárez-Calvet M; Zetterberg H; Blennow K; Schöll M;
Brain; 2021 Feb; 144(1):325-339. PubMed ID: 33257949
[TBL] [Abstract][Full Text] [Related]
12. Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies.
Gonzalez MC; Ashton NJ; Gomes BF; Tovar-Rios DA; Blanc F; Karikari TK; Mollenhauer B; Pilotto A; Lemstra A; Paquet C; Abdelnour C; Kramberger MG; Bonanni L; Vandenberghe R; Hye A; Blennow K; Zetterberg H; Aarsland D;
JAMA Neurol; 2022 Jan; 79(1):32-37. PubMed ID: 34807233
[TBL] [Abstract][Full Text] [Related]
13. The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes.
Jack CR; Wiste HJ; Botha H; Weigand SD; Therneau TM; Knopman DS; Graff-Radford J; Jones DT; Ferman TJ; Boeve BF; Kantarci K; Lowe VJ; Vemuri P; Mielke MM; Fields JA; Machulda MM; Schwarz CG; Senjem ML; Gunter JL; Petersen RC
Brain; 2019 Oct; 142(10):3230-3242. PubMed ID: 31501889
[TBL] [Abstract][Full Text] [Related]
14. Dementia with Lewy bodies: association of Alzheimer pathology with functional connectivity networks.
Schumacher J; Gunter JL; Przybelski SA; Jones DT; Graff-Radford J; Savica R; Schwarz CG; Senjem ML; Jack CR; Lowe VJ; Knopman DS; Fields JA; Kremers WK; Petersen RC; Graff-Radford NR; Ferman TJ; Boeve BF; Thomas AJ; Taylor JP; Kantarci K
Brain; 2021 Nov; 144(10):3212-3225. PubMed ID: 34114602
[TBL] [Abstract][Full Text] [Related]
15. α-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies.
van Steenoven I; Majbour NK; Vaikath NN; Berendse HW; van der Flier WM; van de Berg WDJ; Teunissen CE; Lemstra AW; El-Agnaf OMA
Mov Disord; 2018 Nov; 33(11):1724-1733. PubMed ID: 30440090
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of amnestic patients with hypometabolism patterns suggestive of Lewy body pathology.
Silva-Rodríguez J; Labrador-Espinosa MA; Moscoso A; Schöll M; Mir P; Grothe MJ;
Brain; 2023 Nov; 146(11):4520-4531. PubMed ID: 37284793
[TBL] [Abstract][Full Text] [Related]
17. Imaging tau burden in dementia with Lewy bodies using [
Mak E; Nicastro N; Malpetti M; Savulich G; Surendranathan A; Holland N; Passamonti L; Jones PS; Carter SF; Su L; Hong YT; Fryer TD; Williams GB; Aigbirhio F; Rowe JB; O'Brien JT
Neurobiol Aging; 2021 May; 101():172-180. PubMed ID: 33631469
[TBL] [Abstract][Full Text] [Related]
18. Correlation between Cerebrospinal Fluid Core Alzheimer's Disease Biomarkers and β-Amyloid PET in Chinese Dementia Population.
Xie Q; Ni M; Gao F; Dai LB; Lv XY; Zhang YF; Shi Q; Zhu XX; Xie JK; Shen Y; Wang SC
ACS Chem Neurosci; 2022 May; 13(10):1558-1565. PubMed ID: 35476397
[TBL] [Abstract][Full Text] [Related]
19. Plasma p-tau231, p-tau181, PET Biomarkers, and Cognitive Change in Older Adults.
Meyer PF; Ashton NJ; Karikari TK; Strikwerda-Brown C; Köbe T; Gonneaud J; Pichet Binette A; Ozlen H; Yakoub Y; Simrén J; Pannee J; Lantero-Rodriguez J; Labonté A; Baker SL; Schöll M; Vanmechelen E; Breitner JCS; Zetterberg H; Blennow K; Poirier J; Villeneuve S;
Ann Neurol; 2022 Apr; 91(4):548-560. PubMed ID: 35084051
[TBL] [Abstract][Full Text] [Related]
20. Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer's disease, frontotemporal dementia and progressive supranuclear palsy.
Chouliaras L; Thomas A; Malpetti M; Donaghy P; Kane J; Mak E; Savulich G; Prats-Sedano MA; Heslegrave AJ; Zetterberg H; Su L; Rowe JB; O'Brien JT
J Neurol Neurosurg Psychiatry; 2022 Jun; 93(6):651-658. PubMed ID: 35078917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
